The massive sell-off triggered by the weak Q2 performance has been accelerated by the subsequent negative news-flow in the last few months, sending it back into the value-stock zone. After truncating the sales growth outlook for FY16 from 5-9% to 5-7% and the operating profit growth from 5-9% to 5-8%, Novo Nordisk has, most recently, reported receiving the CRL from the FDA on FIAsp (Faster-Acting Insulin Aspart – a combination of rapid-acting insulin aspart (NovoLog), nicotinimide and a
17 Oct 2016
Correction opens the buying window
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Correction opens the buying window
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
17 Oct 2016 -
Author:
Kamla Singh -
Pages:
3
The massive sell-off triggered by the weak Q2 performance has been accelerated by the subsequent negative news-flow in the last few months, sending it back into the value-stock zone. After truncating the sales growth outlook for FY16 from 5-9% to 5-7% and the operating profit growth from 5-9% to 5-8%, Novo Nordisk has, most recently, reported receiving the CRL from the FDA on FIAsp (Faster-Acting Insulin Aspart – a combination of rapid-acting insulin aspart (NovoLog), nicotinimide and a